JPH08501796A - イブプロフェン−カフェイン配合物 - Google Patents

イブプロフェン−カフェイン配合物

Info

Publication number: JPH08501796A
Authority: JP; Japan
Prior art keywords: ibuprofen; lysine; caffeine; analgesic; pain relief
Prior art date: 1992-09-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP6509126A

Other languages

English (en)

Japanese (ja)

Inventor

シムズ，ロバート・テイー

スリブカ，ウイリアム

マクマホン，ロバート

Original Assignee

メルクエンドカンパニーインコーポレーテッド

マクニール−ピー・ピー・シー・インコーポレイテツド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-29

Filing date

1993-09-21

Publication date

1996-02-27

1993-09-21 Application filed by メルクエンドカンパニーインコーポレーテッド, マクニール−ピー・ピー・シー・インコーポレイテツド filed Critical メルクエンドカンパニーインコーポレーテッド

1996-02-27 Publication of JPH08501796A publication Critical patent/JPH08501796A/ja

Status Pending legal-status Critical Current

Links

229960001948 caffeine Drugs 0.000 title claims abstract description 34
239000000203 mixture Substances 0.000 title claims description 40
238000009472 formulation Methods 0.000 title claims description 14
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 60
208000002193 Pain Diseases 0.000 claims abstract description 40
230000036407 pain Effects 0.000 claims abstract description 39
150000003839 salts Chemical class 0.000 claims abstract description 32
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 30
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 30
HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims abstract description 26
238000011282 treatment Methods 0.000 claims abstract description 20
HEFNNWSXXWATRW-SNVBAGLBSA-N levibuprofen Chemical compound CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-SNVBAGLBSA-N 0.000 claims abstract description 19
230000000202 analgesic effect Effects 0.000 claims abstract description 15
230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 13
206010061218 Inflammation Diseases 0.000 claims abstract description 12
230000004054 inflammatory process Effects 0.000 claims abstract description 12
241000124008 Mammalia Species 0.000 claims abstract description 9
IHHXIUAEPKVVII-PYTFSAHDSA-N (2r)-2,6-diaminohexanoic acid;(2s)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound NCCCC[C@@H](N)C(O)=O.CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 IHHXIUAEPKVVII-PYTFSAHDSA-N 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
IHHXIUAEPKVVII-PTKYJSHISA-N [(5s)-5-amino-5-carboxypentyl]azanium;(2s)-2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound NCCCC[C@H](N)C(O)=O.CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 IHHXIUAEPKVVII-PTKYJSHISA-N 0.000 claims description 33
238000000034 method Methods 0.000 claims description 18
KDXKERNSBIXSRK-YFKPBYRVSA-N L-Lysine Natural products NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 17
230000001737 promoting effect Effects 0.000 claims description 11
241000282412 Homo Species 0.000 claims description 7
230000000694 effects Effects 0.000 claims description 7
230000009467 reduction Effects 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims description 2
TUZRJGVLAFMQEK-FTYBWHBYSA-N (2r)-2-[4-(2-methylpropyl)phenyl]propanoic acid;(2s)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1.CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 TUZRJGVLAFMQEK-FTYBWHBYSA-N 0.000 claims 1
239000004472 Lysine Substances 0.000 abstract description 5
235000002639 sodium chloride Nutrition 0.000 description 31
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 20
229960001680 ibuprofen Drugs 0.000 description 13
-1 Amino acid salts Chemical class 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000013078 crystal Substances 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
239000012452 mother liquor Substances 0.000 description 6
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
IHHXIUAEPKVVII-APFIOPMWSA-N (2s)-2,6-diaminohexanoic acid;(2r)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 IHHXIUAEPKVVII-APFIOPMWSA-N 0.000 description 4
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
206010019233 Headaches Diseases 0.000 description 4
229920003091 Methocel™ Polymers 0.000 description 4
231100000869 headache Toxicity 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229940097964 caffeine 65 mg Drugs 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
235000019739 Dicalciumphosphate Nutrition 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940095534 caffeine 200 mg Drugs 0.000 description 2
229940124827 caffeine tablet Drugs 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000003405 delayed action preparation Substances 0.000 description 2
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
229940038472 dicalcium phosphate Drugs 0.000 description 2
229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
239000002002 slurry Substances 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
239000002904 solvent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
102000009346 Adenosine receptors Human genes 0.000 description 1
108050000203 Adenosine receptors Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010033372 Pain and discomfort Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
206010062519 Poor quality sleep Diseases 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
208000010040 Sprains and Strains Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940023476 agar Drugs 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
150000001484 arginines Chemical class 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
238000007630 basic procedure Methods 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
229940092782 bentonite Drugs 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
229940026622 caffeine 20 mg Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
239000007894 caplet Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000009519 contusion Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
230000029142 excretion Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000007897 gelcap Substances 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP6509126A 1992-09-29 1993-09-21 イブプロフェン−カフェイン配合物 Pending JPH08501796A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US95342392A	1992-09-29	1992-09-29
US953,423		1992-09-29
PCT/US1993/008896 WO1994007471A1 (fr)	1992-09-29	1993-09-21	Association d'ibuprofene et de cafeine

Publications (1)

Publication Number	Publication Date
JPH08501796A true JPH08501796A (ja)	1996-02-27

Family

ID=25493974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP6509126A Pending JPH08501796A (ja)	1992-09-29	1993-09-21	イブプロフェン−カフェイン配合物

Country Status (6)

Country	Link
EP (1)	EP0663819A4 (fr)
JP (1)	JPH08501796A (fr)
AU (1)	AU5132893A (fr)
CA (1)	CA2144152A1 (fr)
MX (1)	MX9306005A (fr)
WO (1)	WO1994007471A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2150355C (fr) *	1992-12-02	2008-03-11	Robert Hardy	Procede d'enrichissenment en un enantiomere donne d'acides phenylpriopioniques au moyen d'alpha-methylbenzylamine
BR9407415A (pt) *	1993-09-07	1996-11-12	Procter & Gamble	Composições contendo um sal de aminoácido de agente antiinflamatório não-esteróide de ácido propiônico e caféina
JPH0987174A (ja) *	1995-09-26	1997-03-31	Kobayashi Pharmaceut Co Ltd	鎮痛性および抗炎症性組成物
US6251945B1 (en) *	1999-01-14	2001-06-26	Knoll Aktiengesellschaft	Pharmaceutical mixture comprising a combination of a profen and other active compounds
US20090238763A1 (en) *	2006-07-09	2009-09-24	Chongxi Yu	High penetration compositions and uses thereof
EP3185861A1 (fr) *	2014-08-28	2017-07-05	Sanofi-Aventis Deutschland GmbH	Composition pharmaceutique pour le traitement de la douleur aiguë des dents ou des mâchoires

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4420483A (en) *	1982-07-22	1983-12-13	Richardson-Vicks, Inc.	Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same
US4558051A (en) *	1983-10-11	1985-12-10	Richardson-Vicks, Inc.	Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4681897A (en) *	1984-01-16	1987-07-21	The Procter & Gamble Company	Pharmaceutical products providing enhanced analgesia
WO1992005783A1 (fr) *	1990-09-28	1992-04-16	Merck & Co., Inc.	Combinaisons d'ibuprofene-antihistamine

1993
- 1993-09-21 WO PCT/US1993/008896 patent/WO1994007471A1/fr not_active Ceased
- 1993-09-21 EP EP93922264A patent/EP0663819A4/fr not_active Withdrawn
- 1993-09-21 AU AU51328/93A patent/AU5132893A/en not_active Abandoned
- 1993-09-21 JP JP6509126A patent/JPH08501796A/ja active Pending
- 1993-09-21 CA CA002144152A patent/CA2144152A1/fr not_active Abandoned
- 1993-09-28 MX MX9306005A patent/MX9306005A/es unknown

Also Published As

Publication number	Publication date
EP0663819A4 (fr)	1998-05-27
MX9306005A (es)	1995-01-31
AU5132893A (en)	1994-04-26
CA2144152A1 (fr)	1994-04-14
WO1994007471A1 (fr)	1994-04-14
EP0663819A1 (fr)	1995-07-26

Legal Events

Date	Code	Title	Description
2004-02-26	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040204
2004-03-22	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040322
2004-05-27	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040506
2005-03-08	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050308
2005-09-15	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050914

Publication	Publication Date	Title
US5331000A (en)	1994-07-19	Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5206029A (en)	1993-04-27	Medicament and its production and use in the treatment of pain, inflammation and fever in man and animals
US4571400A (en)	1986-02-18	Dihydrocodeine/ibuprofen pharmaceutical compositions and method
JPH03206064A (ja)	1991-09-09	速効性かつ鎮痛効果が増強された鎮痛剤としてのｓ（＋）―イブプロフエン―ｌ―アミノ酸とｓ（＋）―イブプロフエン―ｄ―アミノ酸
US5200558A (en)	1993-04-06	S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset-hastened enhanced analgesics
JPH08502254A (ja)	1996-03-12	イブプロフェン−ｈ▲下２▼拮抗薬配合物
JPS63146815A (ja)	1988-06-18	イブプロフェン含有医薬組成物
JPH06506472A (ja)	1994-07-21	イブプロフェン−鎮咳薬配合物
AU9814398A (en)	1999-07-22	Ibuprofen composition
CZ281717B6 (cs)	1996-12-11	Terapeutické činidlo
JPH08503203A (ja)	1996-04-09	新規なアリールプロピオン酸誘導体、その製造方法及び鎮痛薬としてのその用途
US4587252A (en)	1986-05-06	Hydrocodone/ibuprofen pharmaceutical compositions and method
JP2002529407A (ja)	2002-09-10	Ｌ−ｄｏｐａエチルエステル含有分散性組成物
JP2002521329A (ja)	2002-07-16	フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理
JPH0670057B2 (ja)	1994-09-07	グアニン誘導体結晶性一水和物、その製造方法及びそれを含む抗ウイルス剤
JP2002541107A (ja)	2002-12-03	トルペリソンを含有する経口投与のための薬学的製剤
JPH07509715A (ja)	1995-10-26	イブプロフェン−制酸薬配合物
JPH08501796A (ja)	1996-02-27	イブプロフェン−カフェイン配合物
JP2004182705A (ja)	2004-07-02	ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
WO2010120253A1 (fr)	2010-10-21	Combinaisons de thiocolchicoside et de médicament anti-inflammatoire non stéroïdien
WO1994003209A1 (fr)	1994-02-17	Combinaisons dexibuprofene/antacide/simethicone
CN104902891A (zh)	2015-09-09	治疗和预防创伤性脑损伤性神经元损害的组合物和方法
JP3150642B2 (ja)	2001-03-26	新規な抗痙攣性及び抗炎症性組成物並びにそれらの製造方法
JPH08504818A (ja)	1996-05-28	カフェインとｓ（＋）‐イブプロフェン、ｓ（＋）‐フルルビプロフェン又はｓ（＋）‐ケトプロフェンを含有した組成物
WO2022183493A1 (fr)	2022-09-09	Application d'un composé polyphénol